We are committed to expanding our Generics business by targeting complex and alternative dosage form Abbreviated New Drug Applications (ANDAs) with high-value, difficult to develop, first-to-file or first-to-market product opportunities. Our development capabilities are industry-leading and span all dosage forms, including complex oral solids, injectables, ophthalmics, liquids, topicals and transdermals.
The Amneal Generics pipeline is one of the industry’s largest. This pipeline includes products across a broad range of therapeutic areas including cardiovascular, central nervous system/pain, oncology, inflammation, anti-infective, dermatology, endocrinology, diabetes, rhinology, urology, and hematology, among others.
We are also excited about our work to bring patients more affordable biologic therapy options through our growing biosimilars program, which today includes three approved products. We expect to launch these three products over the second half of 2022, along with a full patient support program.